ACVR1 and B-cell non-Hodgkin lymphoma: Our results clearly demonstrated the regulation of BMP‐ACVR1 by PRC2 in B‐cell lymphoma and this signaling is critically required for the anti‐lymphoma efficacy of PRC2 inhibitors.